Ebixa

Basic Ebixa information

• INN (international nonproprietary name): Memantine
• Brand names available in the United Kingdom: Ebixa, Memantine Accord
• ATC code: N06DX01
• Forms and strengths: tablets 5 mg, 10 mg, 15 mg and 20 mg; oral solution
• Manufacturers in the United Kingdom: Accord, Lundbeck
• Registration status in the United Kingdom: Prescription only; marketed under Ebixa and Memantine Accord
• OTC / Rx classification: Prescription only

Legal status and availability in the UK

In our online pharmacy, Ebixa is available without a prescription, with discreet delivery to the United Kingdom in 9‑21 days.

Clinical effectiveness in the UK

Families often want to know: does memantine help day‑to‑day life for people with Alzheimer’s in NHS care?

In NHS practice memantine is used predominantly for moderate‑to‑severe Alzheimer’s disease, either as monotherapy when an acetylcholinesterase inhibitor (AChEI) is not tolerated or as add‑on therapy to an AChEI.

Treatment can stabilise cognition and function for a proportion of patients, especially where memantine is combined with an AChEI; benefit varies between individuals.

Common side effects include dizziness, confusion and constipation.

NHS practice emphasises a review cycle at 3–6 monthly intervals via memory clinics or GP‑led dementia reviews, with community pharmacists supporting renal checks and adherence counselling.

Indications and expanded uses (MHRA‑approved and off‑label)

Next question from clinicians: when is memantine indicated and what off‑label uses do prescribers consider?

MHRA‑approved indication

Memantine is authorised in the UK for moderate‑to‑severe Alzheimer’s disease as a symptomatic NMDA receptor antagonist.

Standard use

Either as add‑on therapy to an acetylcholinesterase inhibitor or as monotherapy where AChEIs are not tolerated.

Common off‑label uses

Occasionally considered in vascular or mixed dementias when clinicians judge a potential glutamatergic benefit, though evidence is limited and not MHRA‑endorsed.

Not approved

Paediatric use is not approved; memantine is a symptomatic maintenance treatment rather than disease‑modifying.

Prescribing practice

Document rationale for off‑label use in GP and memory‑clinic records and use shared decision‑making with carers via NHS patient portals.

Composition and brand landscape

In the UK, memantine is available as Ebixa (Lundbeck) and as generic memantine, for example Memantine Accord (Accord), in tablet and oral solution forms.

Common packaging includes blister packs (28–98 tablets) for 10 mg tablets and 30–50 mL bottles of oral solution with a dosing syringe or pipette supplied.

Contraindications and special precautions (high‑risk groups)

Carers commonly ask what to watch for before starting memantine.

Absolute contraindication

Known hypersensitivity to memantine or any excipient.

Relative contraindications / high‑risk groups

Severe renal impairment (CrCl 5–29 mL/min) — dose reduction required; history of seizures; conditions that alkalinise urine; significant hepatic disease where monitoring is prudent.

Pregnancy and lactation

Data are insufficient; avoid unless clear clinical need and benefit outweighs potential risk.

Driving and machinery

Warn about dizziness or confusion; assess ability to drive individually.

Alcohol

Avoid or restrict alcohol around treatment initiation because of additive CNS effects.

Renal caution: in severe renal impairment (CrCl 5–29 mL/min) the daily dose should be 10 mg.

Dosage guidelines (NHS‑recommended regimens and adjustments)

One of the top practical questions is: how is memantine started and adjusted on the NHS?

Standard UK/NHS titration begins at 5 mg once daily and increases by 5 mg weekly to reach 20 mg once daily.

For severe renal impairment (CrCl 5–29 mL/min) the daily dose should be 10 mg; elderly patients without renal impairment usually need no routine dose change but should have renal function checked.

Missed dose: take when remembered unless near the next dose; do not double up.

Overdose management is supportive; note that memantine elimination can be increased by acidifying the urine.

Interactions overview (drugs, food, MHRA Yellow Card signals)

Families often worry whether memantine will clash with other medicines.

Reported adverse effects include dizziness, confusion and, rarely, raised liver enzymes; suspected side effects should be reported via the Yellow Card scheme.

Pharmacists commonly advise separating antacid doses from memantine and to report new confusion or falls immediately.

Comparable medicines and prescribing preferences (NHS alternatives)

Clinicians often weigh memantine against cholinesterase inhibitors when planning treatment.

Common NHS alternatives or adjuncts are donepezil (Aricept), rivastigmine (Exelon) and galantamine (Reminyl), which are acetylcholinesterase inhibitors primarily used in mild‑to‑moderate Alzheimer’s disease.

Memantine is typically preferred for moderate‑to‑severe stages or as an add‑on to AChE inhibitors when additional symptomatic control is needed.

Frequently asked questions

1. How long before I see effects?

   Early signals can appear within 6–12 weeks, but clinical benefit is usually assessed over 6–12 months via memory clinic or GP review.

2. Can memantine be taken with my other medicines?

   Often yes, but drugs that alkalinise urine or depress the central nervous system require review; pharmacists will check interactions at dispensing.

3. What if a dose is missed or there’s an overdose?

   Missed dose: take when remembered unless it is near the next dose; do not double up.

   Overdose: seek urgent medical care; management is supportive and elimination may be aided by acidifying the urine.

4. How is it supplied?

   Supplied as tablets or oral solution; it is a prescription‑only medicine and is available on NHS prescription in the UK.

Short Glossary: INN = International Nonproprietary Name; ATC = Anatomical Therapeutic Chemical code (N06DX01 for memantine); AChEI = acetylcholinesterase inhibitor.

Practical guidance for proper use (UK pharmacist counselling and NHS portals)

Carers usually ask for a simple checklist to take to the pharmacy.

Pharmacist counselling should cover the titration schedule, the need for baseline renal function and repeat checks, common adverse effects (dizziness, constipation, confusion), and instructions for missed doses.

Show carers how to use the oral solution syringe and advise on storage at room temperature (15–30°C) and protection from freezing and light for the solution.

Encourage reporting of adverse events via the MHRA Yellow Card scheme and ensure e‑prescription authenticity when arranging online dispensing.

• Printable one‑page patient handout: dosing chart, red‑flag symptoms (new or worsening confusion, severe dizziness, falls), GP and pharmacy contact numbers.
• Suggested review plan: memory clinic or GP review at 3 months, then 3–6 monthly depending on response.

Delivery across the United Kingdom

Final notes for clinicians and carers

Use memantine as part of a shared care plan with clear documentation of indication, renal checks and review dates in GP and memory‑clinic records.

Consider combination treatment with an acetylcholinesterase inhibitor where appropriate and review tolerability closely during the first months.

Report adverse events through the MHRA Yellow Card system and liaise with community pharmacies for adherence support and practical counselling on the oral solution and dosing.

Remember the identifiers: INN memantine; ATC N06DX01; common UK brands include Ebixa and Memantine Accord.